BHCM
ATOS icon

Brevan Howard Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Brevan Howard Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-911
Closed -$24.6K – 1063
2024
Q1 		$24.6K Buy
+911
New +$14.6K ﹤0.01% 957

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Brevan Howard Capital Management's ATOS Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Atossa Therapeutics (ATOS) in Q2 2024, closing a stake of 911 shares — an estimated $24.6K sold.

Brevan Howard Capital Management first reported a position in ATOS in Q1 2024 and held it in 1 quarter. The position peaked at $24.6K in Q1 2024. 77 funds tracked by Wall St. Rank hold ATOS as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Atossa Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 911 Atossa Therapeutics shares in Q2 2024, an estimated $24.6K.
  • Brevan Howard Capital Management first reported a position in Atossa Therapeutics in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's Atossa Therapeutics position peaked at $24.6K in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.